Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 17/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585341 | 1.00 | MET (1.00) | METKDRMST1R | |
| SCHEMBL14136735 | 0.88 | MET (0.79) | METKDRMST1R | |
| SCHEMBL304893 | 0.85 | MET (1.00) | METKDRMST1R | |
| SCHEMBL306443 | 0.85 | MET (1.00) | METKDRMST1R | |
| SCHEMBL4880056 | 0.82 | MET (0.70) | METKDRMST1R | |
| SCHEMBL4884342 | 0.82 | MET (0.70) | METKDRMST1R | |
| SCHEMBL4880061 | 0.82 | MET (0.70) | METKDRMST1R | |
| SCHEMBL16177167 | 0.82 | KDR (0.77) | METKDRMST1R | |
| SCHEMBL12251125 | 0.82 | KDR (0.77) | METKDRMST1R | |
| SCHEMBL3563570 | 0.81 | MET (0.79) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885MST1R 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.